Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1981 3
1982 1
1983 1
1984 3
1985 10
1986 7
1987 11
1988 8
1989 15
1990 21
1991 27
1992 42
1993 49
1994 35
1995 52
1996 60
1997 67
1998 74
1999 63
2000 82
2001 91
2002 97
2003 82
2004 102
2005 99
2006 119
2007 147
2008 127
2009 129
2010 125
2011 148
2012 168
2013 185
2014 202
2015 219
2016 260
2017 312
2018 344
2019 372
2020 477
2021 466
2022 465
2023 413
2024 467
2025 36

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,565 results

Results by year

Filters applied: . Clear all
Page 1
Monoclonal Antibody Therapy in Childhood Asthma.
Tison KL, Patrawala M, Blaiss MS. Tison KL, et al. Curr Allergy Asthma Rep. 2020 May 19;20(7):26. doi: 10.1007/s11882-020-00919-3. Curr Allergy Asthma Rep. 2020. PMID: 32430808 Review.
PURPOSE OF REVIEW: There has been an explosion of monoclonal antibodies in the treatment of severe uncontrolled adult asthma. Studies have now been published in severe pediatric asthma. ...Two monoclonal antibodies are approved for childr …
PURPOSE OF REVIEW: There has been an explosion of monoclonal antibodies in the treatment of severe uncontrolled adult asthm …
Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma.
Shinkai M, Yabuta T. Shinkai M, et al. Immunotherapy. 2023 Dec;15(17):1435-1447. doi: 10.2217/imt-2023-0079. Epub 2023 Sep 19. Immunotherapy. 2023. PMID: 37724378 Free article. Review.
Thymic stromal lymphopoietin (TSLP), an epithelial cytokine, is central in the initiation and persistence of airway inflammation in asthma. Tezepelumab is a human immunoglobulin G2lambda (IgG2lambda) monoclonal antibody developed for treating moderate-to-seve …
Thymic stromal lymphopoietin (TSLP), an epithelial cytokine, is central in the initiation and persistence of airway inflammation in asthm …
A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma.
Singh D, Fuhr R, Bird NP, Mole S, Hardes K, Man YL, Cahn A, Yancey SW, Pouliquen IJ. Singh D, et al. Br J Clin Pharmacol. 2022 Feb;88(2):702-712. doi: 10.1111/bcp.15002. Epub 2021 Aug 24. Br J Clin Pharmacol. 2022. PMID: 34292606 Free PMC article. Clinical Trial.
AIMS: GSK3511294 is a humanized anti-interleukin (IL)-5 monoclonal antibody (mAb) engineered for extended half-life and improved IL-5 affinity versus other anti-IL-5 mAbs. ...METHODS: This was a double-blind, parallel-group, single-ascending-dose, multicenter, Phase …
AIMS: GSK3511294 is a humanized anti-interleukin (IL)-5 monoclonal antibody (mAb) engineered for extended half-life and improv …
Current summary of clinical studies on anti-TSLP antibody, Tezepelumab, in asthma.
Kurihara M, Kabata H, Irie M, Fukunaga K. Kurihara M, et al. Allergol Int. 2023 Jan;72(1):24-30. doi: 10.1016/j.alit.2022.11.006. Epub 2022 Dec 2. Allergol Int. 2023. PMID: 36470789 Free article. Review.
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that plays a vital role in the induction of type 2 inflammation via both innate and acquired immune cascades. Tezepelumab, a human IgG2 monoclonal antibody that inhibits the binding of TSLP t …
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that plays a vital role in the induction of type 2 inflammation v …
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Castro M, et al. N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21. N Engl J Med. 2018. PMID: 29782217 Free article. Clinical Trial.
BACKGROUND: Dupilumab is a fully human anti-interleukin-4 receptor alpha monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and safety in patients with uncontrolled asthma. ...CONCLUSIONS: In this trial, …
BACKGROUND: Dupilumab is a fully human anti-interleukin-4 receptor alpha monoclonal antibody that blocks both interleukin-4 an …
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Busse W, et al. J Allergy Clin Immunol. 2001 Aug;108(2):184-90. doi: 10.1067/mai.2001.117880. J Allergy Clin Immunol. 2001. PMID: 11496232 Clinical Trial.
BACKGROUND: A recombinant humanized anti-IgE mAb, omalizumab, forms complexes with free IgE, blocking its interaction with mast cells and basophils; as a consequence, it might be effective in the treatment of asthma. OBJECTIVE: The purpose of this study was to evaluate the …
BACKGROUND: A recombinant humanized anti-IgE mAb, omalizumab, forms complexes with free IgE, blocking its interaction with mast cells and ba …
An Update on Monoclonal Antibody Therapy to Treat Moderate-to-Severe Asthma: Benefits, Choices, and Limitations.
Elliott MR, Grogan CE, Marshall GD. Elliott MR, et al. Am J Med. 2023 Aug;136(8):738-744. doi: 10.1016/j.amjmed.2023.05.001. Epub 2023 May 18. Am J Med. 2023. PMID: 37210021 Review.
Moderate or severe asthma is a complex disease process clinically manifesting as at least partially reversible airway obstruction due to airway hyperresponsiveness. Asthma therapy was based primarily on symptom control until recent studies of its mechanisms have led …
Moderate or severe asthma is a complex disease process clinically manifesting as at least partially reversible airway obstruction due …
Tezepelumab in Adults with Uncontrolled Asthma.
Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, van der Merwe R. Corren J, et al. N Engl J Med. 2017 Sep 7;377(10):936-946. doi: 10.1056/NEJMoa1704064. N Engl J Med. 2017. PMID: 28877011 Free article. Clinical Trial.
BACKGROUND: In some patients with moderate-to-severe asthma, particularly those with noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the efficacy and safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody sp …
BACKGROUND: In some patients with moderate-to-severe asthma, particularly those with noneosinophilic inflammation, the disease remain …
An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease.
Clarke AW, Poulton L, Shim D, Mabon D, Butt D, Pollard M, Pande V, Husten J, Lyons J, Tian C, Doyle AG. Clarke AW, et al. MAbs. 2018 May/Jun;10(4):664-677. doi: 10.1080/19420862.2018.1440164. Epub 2018 Mar 5. MAbs. 2018. PMID: 29436901 Free PMC article.
Given the therapeutic potential of blocking this pathway in IBD and asthma, we developed C03V, a human antibody that binds with high affinity to soluble and membrane-bound TL1A. ...C03V has the potential to address unmet medical needs in asthma and IBD....
Given the therapeutic potential of blocking this pathway in IBD and asthma, we developed C03V, a human antibody that binds wit …
Review of monoclonal antibody therapies in asthma and allergic diseases - a new paradigm for precision medicine.
Lee T, Nair P, Corrigan CJ. Lee T, et al. Asian Pac J Allergy Immunol. 2020 Jun;38(2):78-90. doi: 10.12932/AP-020220-0752. Asian Pac J Allergy Immunol. 2020. PMID: 32563233 Free article. Review.
OBJECTIVE: The drugs that target the cytokine networks pertinent to asthma and allergic diseases are reviewed and some illustrative case histories presented. The overview proposes a framework to use when deciding which monoclonal antibody (mAb) to select for …
OBJECTIVE: The drugs that target the cytokine networks pertinent to asthma and allergic diseases are reviewed and some illustrative c …
5,565 results